Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Litorina in connection with the acquisition of Brödernas
Mandate

Vinge has advised Litorina in connection with the acquisition of Brödernas

June 15, 2021 Employment and Benefits Intellectual Property M&A Environmental Law Real Estate and Construction Banking and Finance IT, Telecommunications and Outsourcing

Brödernas is a fast-growing restaurant chain focused on serving high-quality burger and pizza in Sweden.

Brödernas was founded in 2017 by the brothers Joakim and Jonas Wiklander and early 2019 the brothers Monir Kalgoum and Mika Zibanejad joined as owners. Brödernas has 34 restaurants in Sweden today and an ambitious plan to reach 60-70 restaurants in 2021. Thanks to the partnership, Brödernas can now continue their successful expansion in Sweden and internationally.

Vinge's team consisted of Jonas Johansson together with, among others, Carl Sander, Ellinor Wargenbrant and Gustav Lindgren (M&A), Frida Ställborn, Karolina Cohrs and Ulf Pyk (Real Estate), Lina Österberg (Environment), Seyran Sahin (Banking and Finance), Elin Broman and Ebba Svenburg (Employment), Isabell Nielsen and Alva Hägglund (Commercial Agreements), Felizia Wiker (IP), Mika Jordan (IT) and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026